OpenArc Corporate Advisory’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
Other funds holding JAZZ
OpenArc Corporate Advisory's JAZZ Position: Q2 2026 in Review
OpenArc Corporate Advisory increased its Jazz Pharmaceuticals (JAZZ) stake by 1.5% in Q2 2026, buying an estimated $4.16K and bringing the position to 1,316 shares worth $317K. The position accounts for ﹤0.01% of the portfolio, ranked #613.
OpenArc Corporate Advisory first reported a position in JAZZ in Q1 2026 and has held it in 2 quarters since. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.
- OpenArc Corporate Advisory held 1,316 shares of Jazz Pharmaceuticals worth $317K as of Q2 2026.
- OpenArc Corporate Advisory bought 19 Jazz Pharmaceuticals shares in Q2 2026, an estimated $4.16K.
- Jazz Pharmaceuticals made up ﹤0.01% of OpenArc Corporate Advisory's portfolio in Q2 2026, its #613 holding.
- OpenArc Corporate Advisory first reported a position in Jazz Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
- 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.
Based on OpenArc Corporate Advisory's 13F filing for Q2 2026, filed 5 Aug 2026.